antares pharma inc (ATRS:NASDAQ CM)
antares pharma inc (ATRS) Snapshot
|
Open
$4.05
|
Previous Close
$4.05
|
|
|
Day High
$4.12
|
Day Low
$4.00
|
|
|
52 Week High
07/17/12 - $5.58
|
52 Week Low
06/1/12 - $2.60
|
|
|
Market Cap
518.6M
|
Average Volume 10 Days
1.1M
|
|
|
EPS TTM
$-0.13
|
Shares Outstanding
126.2M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
antares pharma inc (ATRS) Related Businessweek News
antares pharma inc (ATRS) Details
Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies, and topical gel-based medicines worldwide. The company’s products include Tjet/Zomajet, the needle-free auto injectors to deliver human growth hormone treatment to children without the use of a needle; twin-jector EZ II needle free injectors; Medi-Jet auto injectors; Elestrin, an estrogen replacement gel for the treatment of hot flashes; and Gelnique 3%, an oxybutynin gel product for the treatment of overactive bladder. The company is also developing OTREXUP, a product for the delivery of methotrexate using Medi-Jet technology for the treatment of rheumatoid arthritis, poly-articular-course juvenile rheumatoid arthritis, and psoriasis; and VIBEX QS T, an auto injector for the treatment of testosterone deficiency or replacement therapy. In addition, it is developing Vibex auto injectors; disposable pen injectors; and Nestragel, a contraceptive gel. Antares Pharma, Inc. has collaborative and license agreements with Ferring Pharmaceuticals BV; Teva Pharmaceutical Industries, Ltd.; JCR Pharmaceuticals Co., Ltd.; Actavis, Inc.; Daewoong Pharmaceuticals; BioSante Pharmaceuticals, Inc.; Meda Pharmaceuticals; Population Council; and Pfizer Inc. The company was founded in 1979 and is headquartered in Ewing, New Jersey.
antares pharma inc (ATRS) Top Compensated Officers
antares pharma inc (ATRS) Key Developments
Antares Pharma Inc. announced the election of Marvin Samson to the company's Board of Directors. Mr. Samson was formerly Group Vice President -- Worldwide Injectables of Teva, previously having served as Chief Executive Officer and a member of the Board of Directors of Sicor. He was also a founder and CEO of Elkins-Sinn Inc. and Marsam Pharmaceuticals.
Antares Pharma Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, total revenue was $4,528,000 against $6,865,000 for the same period a year ago. Operating loss was $3,404,000 against $97,000 for the same period a year ago. Net loss was $3,409,000 against $74,000 for the same period a year ago. Basic and diluted net loss per common share was $0.03 against $0.00 for the same period a year ago.
Antares Pharma Inc., Q1 2013 Earnings Call, May 08, 2013
| Recently Viewed | |||
| ATRS:US | $4.11 USD | +0.06 |  |
| Company | Last | Change |
| Cerus Corp | $5.16 USD | +0.04 |
| Cytori Therapeutics Inc | $2.50 USD | -0.07 |
| Sequenom Inc | $4.03 USD | -0.05 |
| Staar Surgical Co | $8.78 USD | -0.01 |
| SurModics Inc | $26.28 USD | +0.12 |
| View Industry Companies | ||
Industry Analysis
ATRS
Industry Average
| Valuation | ATRS | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 25.2x |
|
| Price/Book | 6.1x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 21.9x |
|
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact ANTARES PHARMA INC, please visit www.antarespharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
